Jazz 10billion.
post successful phase 1's, and prior to jumping straight into phase 3s this becomes serious buyout target.
Post successful phase 3 the price gets massive - Jazz might just bite the bullet and grab post phase 1.
they have the established customer base but could lower their entire cost base through higher bioavaiabiliyt.
it would be a no brainer for them to take out before it becomes a cheaper more effective competitor.
Ann: EMD-RX5 program advancing Phase 1 clinical trials underway, page-5
Add to My Watchlist
What is My Watchlist?
